Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become a major component of systemic treatment in ER+/HER2− advanced breast cancer, in which they are associated with endocrine therapy and may improve outcomes either in hormone-sensitive or insensitive disease [85,86,87,88,89]. Here, ESR1 is linked to breast cancer.